A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 70 - Any |
| Updated: | 1/18/2019 |
| Start Date: | July 22, 2015 |
| End Date: | December 3, 2018 |
A 24-week Off Drug Extension Parallel Group Study Assessing the Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind Placebo-controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia
A 24-week off drug extension parallel group study assessing the durability of effect on
skeletal muscle strength and function following a 6-month double-blind placebo-controlled
study evaluating bimagrumab in older adults with sarcopenia
skeletal muscle strength and function following a 6-month double-blind placebo-controlled
study evaluating bimagrumab in older adults with sarcopenia
The primary objective is to assess the durability of effect of bimagrumab (BYM338) as
measured by the short physical performance battery (SPPB) total score at week 49.
measured by the short physical performance battery (SPPB) total score at week 49.
Inclusion criterion:
- Men and postmenopausal women aged 70 years or older that have participated in, and have
completed the full study treatment period per protocol (24 weeks/EOT visit) in the
preceding core study (CBYM338E2202)
Exclusion criterion:
- Any condition which should have led to treatment discontinuation per protocol in the core
study (CBYM338E2202)
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials